An update on the topical and oral therapy options for treating pediatric atopic dermatitis

References

• Batmaz SB. Simple markers for systemic inflammation in pediatric atopic dermatitis patients. Indian J Dermatol. 2018;63(4):305–310.
   PubMed Web of Science ®Google Scholar
• Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66(Suppl 1):8–16.
   PubMed Web of Science ®Google Scholar
• Asher MI, Montefort S, Bjorksten B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC phases one and three repeat multicountry cross-sectional surveys. Lancet. 2006;368(9537):733–743.
   PubMed Web of Science ®Google Scholar
• Shaw TE, Currie GP, Koudelka CW, et al. Eczema prevalence in the United States: data from the 2003 National Survey of Children’s Health. J Invest Dermatol. 2011;131(1):67–73.
   PubMed Web of Science ®Google Scholar
• Sullivan M, Silverberg NB. Current and emerging concepts in atopic dermatitis pathogenesis. Clin Dermatol. 2017;35(4):349–353.
   PubMed Web of Science ®Google Scholar
• Gutman AB, Kligman AM, Sciacca J, et al. Soak and smear: a standard technique revisited. Arch Dermatol. 2005;141(12):1556–1559.
   PubMedGoogle Scholar
• Tollefson MM, Bruckner AL. Atopic dermatitis: skin-directed management. Pediatrics. 2014;134(6):e1735–1744.
   PubMed Web of Science ®Google Scholar
• Cheong WK. Gentle cleansing and moisturizing for patients with atopic dermatitis and sensitive skin. Am J Clin Dermatol. 2009;10(Suppl 1):13–17.
   PubMedGoogle Scholar
• Hajar T, Hanifin JM, Tofte SJ, et al. Prehydration is effective for rapid control of recalcitrant atopic dermatitis. Dermat Contact Atop Occupat Drug. 2014;25(2):56–59.
   PubMed Web of Science ®Google Scholar
• Chiang C, Eichenfield LF. Quantitative assessment of combination bathing and moisturizing regimens on skin hydration in atopic dermatitis. Pediatr Dermatol. 2009;26(3):273–278.
   PubMed Web of Science ®Google Scholar
• Lyons JJ, Milner JD, Stone KD. Atopic dermatitis in children: clinical features, pathophysiology, and treatment. Immunol Allergy Clin North Am. 2015;35(1):161–183.
   PubMed Web of Science ®Google Scholar
• Breternitz M, Kowatzki D, Langenauer M, et al. Placebo-controlled, double-blind, randomized, prospective study of a glycerol-based emollient on eczematous skin in atopic dermatitis: biophysical and clinical evaluation. Skin Pharmacol Physiol. 2008;21(1):39–45.
   PubMed Web of Science ®Google Scholar
• Draelos ZD. An evaluation of prescription device moisturizers. J Cosmet Dermatol. 2009;8(1):40–43.
   PubMed Web of Science ®Google Scholar
• Galli E, Neri I, Ricci G, et al. Consensus conference on clinical management of pediatric atopic dermatitis. Ital J Pediatr. 2016;42:26.
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116–132.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Oranje A, Deleuran M, et al. ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. J Eur Acad Dermatol Venereol. 2016;30(5):729–747.
   PubMed Web of Science ®Google Scholar
• Strathie Page S, Weston S, Loh R. Atopic dermatitis in children. Aust Fam Physician. 2016;45(5):293–296.
   PubMed Web of Science ®Google Scholar
• Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol. 2012;26(8):1045–1060.
   PubMed Web of Science ®Google Scholar
• Tan AU, Gonzalez ME. Management of severe atopic dermatitis in children. J Drugs Dermatol. 2012;11(10):1158–1165.
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Totri C. Optimizing outcomes for paediatric atopic dermatitis. Br J Dermatol. 2014;170(Suppl 1):31–37.
   PubMedGoogle Scholar
• Hong E, Smith S, Fischer G. Evaluation of the atrophogenic potential of topical corticosteroids in pediatric dermatology patients. Pediatr Dermatol. 2011;28(4):393–396.
   PubMed Web of Science ®Google Scholar
• Awasthi S, Rothe MJ, Eichenfield LF. Atopic dermatitis: kids are not just little people. Clin Dermatol. 2015;33(6):594–604.
   PubMed Web of Science ®Google Scholar
• Kirsner RS, Heffernan MP, Antaya R. Safety and efficacy of tacrolimus ointment versus pimecrolimus cream in the treatment of patients with atopic dermatitis previously treated with corticosteroids. Acta Derm Venereol. 2010;90(1):58–64.
   PubMed Web of Science ®Google Scholar
• Carr WW. Topical calcineurin inhibitors for atopic dermatitis: review and treatment recommendations. Paediatr Drugs. 2013;15(4):303–310.
   PubMed Web of Science ®Google Scholar
• Thaci D, Reitamo S, Gonzalez Ensenat MA, et al. Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. Br J Dermatol. 2008;159(6):1348–1356.
   PubMed Web of Science ®Google Scholar
• Luger T, Boguniewicz M, Carr W, et al. Pimecrolimus in atopic dermatitis: consensus on safety and the need to allow use in infants. Pediatr Allergy Immunol. 2015;26(4):306–315.
   PubMed Web of Science ®Google Scholar
• Paller AS, Eichenfield LF, Kirsner RS, et al. Three times weekly tacrolimus ointment reduces relapse in stabilized atopic dermatitis: a new paradigm for use. Pediatrics. 2008;122(6):e1210–1218.
   PubMed Web of Science ®Google Scholar
• CID=32798. PubChem compound database. [cited 2018 Sept 9] Available from: https://pubchem.ncbi.nlm.nih.gov/compound/32798
   Google Scholar
• CID=445643. PubChem compound database. [cited 2018 Sept 9] Available from: https://pubchem.ncbi.nlm.nih.gov/compound/445643
   Google Scholar
• CID=6509979. PubChem compound database. [cited 2018 Sept 9]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/6509979
   Google Scholar
• Siegfried EC, Jaworski JC, Kaiser JD, et al. Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis. BMC Pediatr. 2016;16:75.
   PubMed Web of Science ®Google Scholar
• Sigurgeirsson B, Boznanski A, Todd G, et al. Safety and efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial. Pediatrics. 2015.
   Google Scholar
• Ohtsuki M, Morimoto H, Nakagawa H. Tacrolimus ointment for the treatment of adult and pediatric atopic dermatitis: review on safety and benefits. J Dermatol. 2018;45(8):936–942.
   Google Scholar
• Margolis DJ, Abuabara K, Hoffstad OJ, et al. Association between malignancy and topical use of pimecrolimus. JAMA Dermatol. 2015;151(6):594–599.
   PubMed Web of Science ®Google Scholar
• Hoy SM. Crisaborole ointment 2%: a review in mild to moderate atopic dermatitis. Am J Clin Dermatol. 2017;18(6):837–843.
   PubMed Web of Science ®Google Scholar
• Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 2016;75(3):494–503.e496.
   PubMed Web of Science ®Google Scholar
• Broeders JA, Ahmed Ali U, Fischer G. Systematic review and meta-analysis of randomized clinical trials (RCTs) comparing topical calcineurin inhibitors with topical corticosteroids for atopic dermatitis: A 15-year experience. J Am Acad Dermatol. 2016;75(2):410–419.e413.
   PubMed Web of Science ®Google Scholar
• Slater NA, Morrell DS. Systemic therapy of childhood atopic dermatitis. Clin Dermatol. 2015;33(3):289–299.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Bruin-Weller M, Flohr C, et al. When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. J Am Acad Dermatol. 2017;77(4):623–633.
   PubMed Web of Science ®Google Scholar
• Flohr C, Irvine AD. Systemic therapies for severe atopic dermatitis in children and adults. J Allergy Clin Immunol. 2013;132(3):774–774.e776.
   PubMed Web of Science ®Google Scholar
• Caufield M, Tom WL. Oral azathioprine for recalcitrant pediatric atopic dermatitis: clinical response and thiopurine monitoring. J Am Acad Dermatol. 2013;68(1):29–35.
   PubMed Web of Science ®Google Scholar
• Chong JH, Koh MJA. Non-topical management of recalcitrant paediatric atopic dermatitis. Arch Dis Child. 2017;102(7):681–686.
   PubMed Web of Science ®Google Scholar
• Waxweiler WT, Agans R, Morrell DS. Systemic treatment of pediatric atopic dermatitis with azathioprine and mycophenolate mofetil. Pediatr Dermatol. 2011;28(6):689–694.
   PubMed Web of Science ®Google Scholar
• Fuggle NR, Bragoli W, Mahto A, et al. The adverse effect profile of oral azathioprine in pediatric atopic dermatitis, and recommendations for monitoring. J Am Acad Dermatol. 2015;72(1):108–114.
   PubMed Web of Science ®Google Scholar
• Dehesa L, Abuchar A, Nuno-Gonzalez A, et al. The use of cyclosporine in dermatology. J Drugs Dermatol. 2012;11(8):979–987.
   PubMed Web of Science ®Google Scholar
• Simon D, Bieber T. Systemic therapy for atopic dermatitis. Allergy. 2014;69(1):46–55.
   PubMed Web of Science ®Google Scholar
• Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71(2):327–349.
   PubMed Web of Science ®Google Scholar
• Charbit L, Mahe E, Phan A, et al. Systemic treatments in childhood psoriasis: a French multicentre study on 154 children. Br J Dermatol. 2016;174(5):1118–1121.
   PubMed Web of Science ®Google Scholar
• Di Lernia V, Stingeni L, Boccaletti V, et al. Effectiveness and safety of cyclosporine in pediatric plaque psoriasis: a multicentric retrospective analysis. J Dermatolog Treat. 2016;27(5):395–398.
   PubMed Web of Science ®Google Scholar
• El-Khalawany MA, Hassan H, Shaaban D, et al. Methotrexate versus cyclosporine in the treatment of severe atopic dermatitis in children: a multicenter experience from Egypt. Eur J Pediatr. 2013;172(3):351–356.
   PubMed Web of Science ®Google Scholar
• Deo M, Yung A, Hill S, et al. Methotrexate for treatment of atopic dermatitis in children and adolescents. Int J Dermatol. 2014;53(8):1037–1041.
   PubMed Web of Science ®Google Scholar
• Rahman SI, Siegfried E, Flanagan KH, et al. The methotrexate polyglutamate assay supports the efficacy of methotrexate for severe inflammatory skin disease in children. J Am Acad Dermatol. 2014;70(2):252–256.
   PubMed Web of Science ®Google Scholar
• Notaro ER, Sidbury R. Systemic agents for severe atopic dermatitis in children. Paediatr Drugs. 2015;17(6):449–457.
   PubMed Web of Science ®Google Scholar
• Downing HJ, Pirmohamed M, Beresford MW, et al. Paediatric use of mycophenolate mofetil. Br J Clin Pharmacol. 2013;75(1):45–59.
   PubMed Web of Science ®Google Scholar
• Hamilton JD, Ungar B, Guttman-Yassky E. Drug evaluation review: dupilumab in atopic dermatitis. Immunotherapy. 2015;7(10):1043–1058.
   PubMed Web of Science ®Google Scholar
• Beck LA, Thaci D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130–139.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–2348.
   PubMed Web of Science ®Google Scholar
• Kraft M, Worm M. Dupilumab in the treatment of moderate-to-severe atopic dermatitis. Expert Rev Clin Immunol. 2017;13(4):301–310.
   PubMed Web of Science ®Google Scholar
• DUPIXENT (dupilumab) [package insert]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc/sanofi-aventis U.S. LLC; 2018.
   Google Scholar
• Nygaard U, Vestergaard C, Deleuran M. Emerging treatment options in atopic dermatitis: systemic therapies. Dermatology. 2017;233(5):344–357.
   PubMed Web of Science ®Google Scholar
• Thaci D, Simpson EL, Beck LA, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2016;387(10013):40–52.
   PubMed Web of Science ®Google Scholar
• Abdulrahim H, Thistleton S, Adebajo AO, et al. Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis. Expert Opin Pharmacother. 2015;16(7):1099–1108.
   PubMed Web of Science ®Google Scholar
• Saporito RC, Cohen DJ. Apremilast use for moderate-to-severe atopic dermatitis in pediatric patients. Case Rep Dermatol. 2016;8(2):179–184.
   PubMed Web of Science ®Google Scholar
• Samrao A, Berry TM, Goreshi R, et al. A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults. Arch Dermatol. 2012;148(8):890–897.
   PubMedGoogle Scholar
• Zebda R, Paller AS. Phosphodiesterase 4 inhibitors. J Am Acad Dermatol. 2018;78(3s1):S43–s52.
   PubMed Web of Science ®Google Scholar
• Cotter DG, Schairer D, Eichenfield L. Emerging therapies for atopic dermatitis: JAK inhibitors. J Am Acad Dermatol. 2018;78(3s1):S53–s62.
   PubMedGoogle Scholar
• Damsky W, King BA. JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol. 2017;76(4):736–744.
   PubMed Web of Science ®Google Scholar